Perspective Therapeutics (CATX) EBT Margin Growth (3y) (2013 - 2023)
Powered by 
Analysis
Perspective Therapeutics (CATX) EBT Margin Growth (3y) (2013 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 443.00 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -15,548.00 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -484.00 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 132.00 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 6,691.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -2,054.00 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 9,980.00 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,399.00 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 31,363.00 |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 38,004.00 |
| Sep 30, 2023 | -44,405.00 |
| Jun 30, 2023 | -47,977.00 |
| Mar 31, 2023 | -50,803.00 |
| Sep 30, 2022 | -6,981.00 |
| Jun 30, 2022 | -634.00 |
| Mar 31, 2022 | 1,239.00 |
| Dec 31, 2021 | 1,730.00 |
| Sep 30, 2021 | 906.00 |
| Jun 30, 2021 | 10,795.00 |
| Mar 31, 2021 | 5,603.00 |
| Dec 31, 2020 | 5,845.00 |
| Sep 30, 2020 | 9,776.00 |
| Jun 30, 2020 | 8,181.00 |
| Mar 31, 2020 | 8,716.00 |
| Dec 31, 2019 | 10,039.00 |
| Sep 30, 2019 | 10,767.00 |
| Jun 30, 2019 | 5,041.00 |
| Mar 31, 2019 | 4,758.00 |
| Dec 31, 2018 | 3,961.00 |